ClinicalTrials.gg
Not yet recruitingNCT06561009Updated Oct 16, 2026

Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder

A Phase 1/2 interventional study of Anti-BAFFR CART in Neuromyelitis Optica Spectrum Disorder, sponsored by Tianjin Medical University General Hospital. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Tianjin Medical University General Hospital · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 16, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Neuromyelitis Optica by Tianjin Medical University General Hospital — 5 open to participants now, 8 under way, 3 of them phase 3. Neuromyelitis Optica · Tianjin Medical University General Hospital.

Planned enrollment
8th of 14
20 · median 24
Started
2026
with 1 other
Phase 1/2
4 of 15
2 open now
Registered
10th of 15
by date

Among the 15 studies in Neuromyelitis Optica by Tianjin Medical University General Hospital, this one is the 8th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 1/2, and was the 10th registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

5 of the 15 studies in Neuromyelitis Optica by Tianjin Medical University General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Neuromyelitis Optica by Tianjin Medical University General Hospital, or all of them as a file.
02

Study summary

This is an open-label, single-arm, dose-escalation study in up to 20 participants with relapsed/refractory Neuromyelitis Optica Spectrum Disorders (NMOSD). The aim is to evaluate the safety and efficacy of the treatment with BAFFR CART.

03

Conditions studied

  • Neuromyelitis Optica Spectrum Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 18-60 years;
  2. Patients must be diagnosed as AQP4-IgG-positive NMOSD;
  3. At least one has been used for over a year with poorly controlled symptoms;
  4. Clinical evidence of at least two relapses in the last 12 months or three relapses in the last 24 months and one relapse in the preceding 12 months before screening.
  5. Subjects and their partners must be willing to use effective and reliable methods of , devices or medicines, within one year before BAFFR CART cells infusion.
  6. Subjects must provide written before the study begins and comply with the requirements of the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Subjects have received B cell deletion treatment within 6 months before screening;
  2. Chronic and active (HBV), (HCV), (HIV) infection, CMV or syphilis infections concurrently.
  3. Subjects with Papovaviruses infection.
  4. Subjects have received vaccination within 8 weeks before screening; or plan to receive live vaccine vaccination within 8 weeks after treatment;
  5. History of psychoactive drug abuse and failed to withdraw, or have a history of psychiatric disorders.
  6. Pregnant or lactating women.
  7. Subjects with severe heart, liver, kidney or bone marrow function disorder.
  8. Allergic constitution or a history of severe allergies.
  9. Subjects with conditions adjudicated by the investigator as unsuitable for lymphodepletion or cell infusion.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Participant Group

    BAFFR CART cells

    Drug: Anti-BAFFR CART

Interventions

  • DrugAnti-BAFFR CART

    Anti-BAFFR CART

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicity (DLT)

    Incidence of dose-limiting toxicity (DLT) will be evaluated within the first 28 days following BAFFR CART cells infusion.

    Time frame: Up to 28 days

  2. Incidence and severity of adverse events

    Adverse events will be evaluated following the chemotherapy preparative regimen and infusion of BAFFR CART cells within the first 28 days.

    Time frame: Up to 28 days

Secondary outcomes

  1. Proportion of BAFFR CART cells in peripheral blood

    The proportion of BAFFR CART cells in peripheral blood will be detected after infusion.

    Time frame: Up to 1 years

  2. Annualized relapse rate (ARR)

    ARR is defined as the number of attacks divided by the total participant-years after infusion.

    Time frame: Up to 1 years

  3. Changes of B cell levels in bone marrow and peripheral blood

    The changes of B cell levels in bone marrow and peripheral blood after BAFFR CART infusion.

    Time frame: Up to 1 years

  4. Changes of AQP4 antibody titers

    Changes of AQP4 antibody titers from baseline over 1 year after BAFFR CART infusion.

    Time frame: Up to 1 years

  5. Changes of cytokine in peripheral blood

    Changes of cytokine(including IL-6, IFN-γ, TNF-α, and serum BAFF) in peripheral blood from baseline over 1 year after BAFFR CART infusion.

    Time frame: Up to 1 years

  6. Changes of Expanded Disability Status Scale (EDSS) score

    Participant will be considered to have a worsening in overall EDSS score of at least 2 if baseline EDSS score was 0, or at least 1 point if baseline EDSS score is 1 to 5, or at least 0.5 point if baseline EDSS score is 5.5 or more.

    Time frame: Up to 1 years

  7. Changes of visual acuity

    Corrected visual acuity is determine by Snellen E chart held at a distance of 5 meters.

    Time frame: Up to 1 years

  8. Accumulated total active MRI lesions

    The changes of T2 lesions and/or enhancing T1 Lesions as detected by brain Magnetic Resonance Imaging (MRI).

    Time frame: Up to 1 years

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Oct 2027, 10 months later.

Start moved once since we started tracking on Sep 25, 2026: Dec 2025 → Dec 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2024
First posted
Aug 19, 2024
StartEst.
Dec 1, 2026was Dec 2025
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 1, 2025→Dec 1, 2026
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Start date Dec 1, 2025→Dec 1, 2026
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06561009
Lead sponsor
Tianjin Medical University General Hospital
Responsible party
Qiang Liu (Department of Neurology, Tianjin Medical University General Hospital) — Principal investigator
First posted
Aug 19, 2024
Start date
Dec 1, 2026 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Oct 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion